文献速递垂体与肾上腺疾病

卡麦角林与氯喹联合抑制垂体瘤

Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究探讨多巴胺激动剂卡麦角林(CAB)与氯喹(CQ)联合能否协同抑制垂体腺瘤及其他癌症生长。体外实验使用大鼠垂体瘤细胞系MMQ和GH3、人垂体瘤原代培养及多种人癌细胞系,并在裸鼠异种移植模型和雌激素诱导的大鼠催乳素瘤中验证。结果显示CQ增强CAB对细胞增殖的抑制,低剂量CAB联合CQ阻断自噬流并诱导凋亡。

要点

  • CQ增强CAB对垂体瘤细胞增殖的抑制,并在体内异种移植和雌激素诱导大鼠催乳素瘤模型中验证。
  • 低剂量CAB联合CQ阻断正常自噬周期并诱导凋亡,伴p62/caspase-8/LC3-II进一步积累。
  • 数据提示CAB联合CQ可能提高人垂体腺瘤及其他癌症的治疗效果。

核心结论

  • 数据提示CAB与CQ联合使用可能提高人垂体腺瘤及其他癌症的临床疗效,使其成为肿瘤和癌症治疗中有吸引力的选择。

研究设计与样本

  • 体外研究使用大鼠垂体瘤细胞系MMQ和GH3、人垂体瘤细胞原代培养及若干人癌细胞系。
  • 体内研究在裸鼠异种移植模型和雌激素诱导的大鼠催乳素瘤中进行验证。
  • 建立低CAB剂量条件,该条件下CAB能诱导自噬但未能抑制细胞生长。

主要发现

  • 体外研究显示CQ增强CAB对细胞增殖的抑制。
  • 上述结果在裸鼠异种移植模型和雌激素诱导的大鼠催乳素瘤中得到证实。
  • 低剂量CAB加用CQ阻断正常自噬周期并诱导凋亡,表现为p62/caspase-8/LC3-II进一步积累。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The dopamine agonist cabergoline (CAB) has been used widely in the treatment of prolactinomas and other types of pituitary adenomas, but its clinical use is hampered by intolerance in some patients with prolactinoma and lack of effectiveness in other pituitary tumor types. Chloroquine (CQ) is an old drug widely used to treat malaria. Recent studies, including our own, have revealed that CAB and CQ are involved in induction of autophagy and activation of autophagic cell death. OBJECTIVE: To test whether CAB and CQ can function cooperatively to suppress growth of pituitary adenomas as well as other cancers. RESULTS: In vitro studies using the rat pituitary tumor cell lines MMQ and GH3, human pituitary tumor cell primary cultures, and several human cancer cell lines showed that CQ enhanced suppression of cell proliferation by CAB. These results were confirmed in in vivo xenograft models in nude mice and estrogen-induced rat prolactinomas. To understand the mechanism of combined CAB and CQ action, we established a low-CAB-dose condition in which CAB was able to induce autophagy but failed to suppress cell growth. Addition of CQ to low-dose CAB blocked normal autophagic cycles and induced apoptosis, evidenced by the further accumulation of p62/caspase-8/LC3-II. CONCLUSION: The data suggest that combined use of CAB and CQ may increase clinical effectiveness in treatment of human pituitary adenomas, as well as other cancers, making it an attractive option in tumor and cancer therapies.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lin SJ, Wu ZR, Cao L, et al. Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine. J Clin Endocrinol Metab. 2017. PMID: 28973192. doi:10.1210/jc.2017-00627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。